Compare LQDA & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | QLYS |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2020 | 2012 |
| Metric | LQDA | QLYS |
|---|---|---|
| Price | $39.41 | $83.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | $41.00 | ★ $136.00 |
| AVG Volume (30 Days) | ★ 964.7K | 794.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | 16.99 |
| EPS | N/A | ★ 5.44 |
| Revenue | $158,320,000.00 | ★ $321,607,000.00 |
| Revenue This Year | $278.87 | $9.97 |
| Revenue Next Year | $57.13 | $7.15 |
| P/E Ratio | ★ N/A | $15.47 |
| Revenue Growth | ★ 1031.18 | 15.32 |
| 52 Week Low | $11.85 | $74.51 |
| 52 Week High | $46.67 | $155.47 |
| Indicator | LQDA | QLYS |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 40.12 |
| Support Level | $31.75 | $74.51 |
| Resistance Level | $46.67 | $92.02 |
| Average True Range (ATR) | 2.01 | 4.41 |
| MACD | 0.27 | 0.37 |
| Stochastic Oscillator | 62.95 | 48.09 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.